ReviewBiological psychiatry2024
Prescription Digital Therapeutics: An Emerging Treatment Option for Negative Symptoms in Schizophrenia.
Review in Biological psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- AI-enabled passive digital phenotyping of experiential negative symptoms in schizophrenia-spectrum disorders: a narrative review on the path from sensing to clinical endpoints.Frontiers in psychiatry · 2026Review
- Multimodal and Multidimensional Artificial Intelligence Technology in Obesity.Journal of obesity & metabolic syndrome · 2025Review
- Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial.JMIR research protocols · 2025Article
- Digital therapeutics for cognitive impairments associated with schizophrenia: our opinion.Frontiers in psychiatry · 2025Article
- Patient Perspectives on a Digital Therapeutic for Schizophrenia: A Qualitative Evaluation of an App for Negative Symptoms.Schizophrenia bulletin open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Digital therapeutics-web-based programs, smartphone applications, and wearable devices designed to prevent, treat, or manage clinical conditions through software-driven, evidence-based intervention-can provide accessible alternatives and/or may supplement standard care for patients with serious mental illnesses, including schizophrenia. In this article, we provide a targeted summary of the rapidly growing field of digital therapeutics for schizophrenia and related serious mental illnesses. First, we define digital therapeutics. Then, we provide a brief summary of the emerging evidence of the efficacy of digital therapeutics for improving clinical outcomes, focusing on potential mechanisms of action for addressing some of the most challenging problems, including negative symptoms of psychosis. Our focus on these promising targets for digital therapeutics, including the latest in prescription models in the commercial space, highlights future directions for research and practice in this exciting field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.